Arming Cytokine-induced Killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation"

Molecular Therapy

Volumn 21, Issue 12, 2013, Pages 2268-2277

  Hombach, Andreas A ^a,b   Rappl, Gunter ^a,b   Abken, Hinrich ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD28 ANTIGEN; CHIMERIC PROTEIN; GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ENGINEERING; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL STIMULATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD56; CELL DEATH; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; HEK293 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84890117209     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.192     Document Type: Article

References (31)

1. Schmidt-Wolf, IG, Negrin, RS, Kiem, HP, Blume, KG and Weissman, IL (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149
2. Donia, M, Junker, N, Ellebaek, E, Andersen, MH, Straten, PT and Svane, IM (2011). Characterization and comparison of "Standard" and "Young" tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol (epub ahead of print
3. Nishimura, R, Baker, J, Beilhack, A, Zeiser, R, Olson, JA, Sega, EI et al. (2008). In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112: 2563-2574
4. Ma, Y, Zhang, Z, Tang, L, Xu, YC, Xie, ZM, Gu, XF et al. (2012). Cytokine-induced killer cells in the treatment of patients with solid carcinomas: A systematic review and pooled analysis. Cytotherapy 14: 483-493
5. Franceschetti, M, Pievani, A, Borleri, G, Vago, L, Fleischhauer, K, Golay, J et al. (2009). Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 37: 616-628.e2
6. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733
7. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73
8. Lizée, G, Cantu, MA and Hwu, P (2007). Less yin, more yang: Confronting the barriers to cancer immunotherapy. Clin Cancer Res 13(18 Pt 1): 5250-5255
9. Rossig, C, Bollard, CM, Nuchtern, JG, Rooney, CM and Brenner, MK (2002). Epstein- Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood 99: 2009-2016
10. Shrikant, P and Mescher, MF (1999). Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 162: 2858-2866
11. Hombach, AA, Holzinger, A and Abken, H (2013). The Weal and Woe of Costimulation in the Adoptive Therapy of Cancer with Chimeric Antigen Receptor (CAR)-Redirected T Cells. Curr Mol Med 13: 1079-1088
12. Hombach, AA and Abken, H (2011). Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 129: 2935-2944
13. Lu, PH and Negrin, RS (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696
14. Mesiano, G, Todorovic, M, Gammaitoni, L, Leuci, V, Giraudo Diego, L, Carnevale- Schianca, F et al. (2012). Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12: 673-684
15. Verneris, MR, Karami, M, Baker, J, Jayaswal, A and Negrin, RS (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072
16. Pende, D, Cantoni, C, Rivera, P, Vitale, M, Castriconi, R, Marcenaro, S et al. (2001). Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31: 1076-1086
17. Marin, V, Pizzitola, I, Agostoni, V, Attianese, GM, Finney, H, Lawson, A et al. (2010). Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: Improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95: 2144-2152
18. Pizzitola, I, Agostoni, V, Cribioli, E, Pule, M, Rousseau, R, Finney, H et al. (2011). In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J Immunother 34: 469-479
19. Schlimper, C, Hombach, AA, Abken, H and Schmidt-Wolf, IG (2012). Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012: 238924
20. Hombach, AA, Heiders, J, Foppe, M, Chmielewski, M and Abken, H (2012). OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 1: 458-466
21. Hombach, AA, Chmielewski, M, Rappl, G and Abken, H (2013). Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther 24: 259-269
22. Sangiolo, D, Martinuzzi, E, Todorovic, M, Vitaggio, K, Vallario, A, Jordaney, N et al. (2008). Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers. Int Immunol 20: 841-848
23. Rettinger, E, Kuçi, S, Naumann, I, Becker, P, Kreyenberg, H, Anzaghe, M et al. (2012). The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14: 91-103
24. Todorovic, M, Mesiano, G, Gammaitoni, L, Leuci, V, Giraudo Diego, L, Cammarata, C et al. (2012). Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother 35: 579-586
25. Weijtens, ME, Willemsen, RA, Hart, EH and Bolhuis, RL (1998). A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther 5: 1195-1203
26. Kaulen, H, Seemann, G, Bosslet, K, Schwaeble, W and Dippold, W (1993). Humanized anti-carcinoembryonic antigen antibody: Strategies to enhance human tumor cell killing. Year Immunol 7: 106-109
27. Hombach, A, Sent, D, Schneider, C, Heuser, C, Koch, D, Pohl, C et al. (2001). T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptormediated target cell lysis. Cancer Res 61: 1976-1982
28. Hombach, A, Schlimper, C, Sievers, E, Frank, S, Schild, HH, Sauerbruch, T et al. (2006). A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55: 1156-1164
29. Hombach, A, Wieczarkowiecz, A, Marquardt, T, Heuser, C, Usai, L, Pohl, C et al. (2001). Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167: 6123-6131
30. Jost, LM, Kirkwood, JM and Whiteside, TL (1992). Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 147: 153-165
31. Duan, F, Simeone, S, Wu, R, Grady, J, Mandoiu, I and Srivastava, PK (2012). Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J Immunol Methods 382: 224-228